All Stories

  1. Developing personalized treatment strategies for Parkinson’s disease based on disease subtypes
  2. Genotype-phenotype association study conducted on LARGE-PD reveals novel loci associated with Parkinson’s Disease
  3. Condiciones de igualdad entre médicas y médicos en 2021 en el Instituto Nacional de Neurología y Neurocirugía
  4. Influencia del sexo y del estado funcional en el bienestar emocional en la enfermedad de Parkinson: conocimientos de un estudio transversal
  5. Establishing a MoCA cut-off point for cognitive impairment detection in Mexican people living with Parkinson's disease: A comprehensive assessment (level II) approach
  6. Differences and contributors to global cognitive performance in the underrepresented Latinx Parkinson’s disease population
  7. Revisión exploratoria sobre los tratamientos experimentales para la enfermedad de Parkinson: terapias de precisión y de amplio espectro
  8. Factores de riesgo para el desarrollo de trastornos del control de impulsos en sujetos mexicanos con enfermedad de Parkinson
  9. Breaking the gender barrier: a study on enrollment trends in medical specialties at the Universidad Nacional Autónoma de México
  10. Association between alterations in sleep spindles and cognitive decline in persons with Parkinson’s disease
  11. Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study
  12. Weak association between total alpha‐synuclein reflex tear levels and non‐motor symptoms burden in Parkinson's disease
  13. Movement disorders in opioid users observed in the social networks: a systematic review
  14. A Characterization of Central Auditory Processing in Parkinson’s Disease
  15. The Importance of Standardized Assessment
  16. Levodopa Versus Levodopa Sparing in Early Parkinson‘s Disease: Can we Meet Halfway?
  17. Electrocardiographic approach strategies in patients with Parkinson disease treated with deep brain stimulation
  18. Establishment of induced pluripotent stem cell lines derived from Parkinson’s disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1
  19. Parkinson's disease-associated pain in a Mexican Institute
  20. Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease
  21. Pro-inflammatory cytokines levels in tears and dry eye disease in Parkinson’s disease
  22. Investigación en enfermería: Una visión actual
  23. Neuropsychiatric and young-onset as clinical determinants for a delayed HuntingtonÓ?s disease diagnosis
  24. Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset
  25. Determinants and impact of alexithymia on quality of life in Parkinson's disease
  26. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease?
  27. Association between cardiometabolic comorbidities and Parkinson’s disease in a Mexican population
  28. Experience with Creutzfeldt-Jakob disease in a single referral center in Mexico. Case series
  29. Association between dopaminergic-induced complications and life satisfaction in ParkinsonÓ?s disease
  30. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson’s disease
  31. Pitfalls and caveats in the diagnostic pathway of people with ParkinsonÓ?s disease
  32. Experiencia con la enfermedad de Creutzfeldt-Jakob de un único centro de referencia en México. Análisis de una serie de casos
  33. Fellowship training: a collateral damage of Covid-19 pandemic
  34. Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
  35. Satisfaction With Telemedicine Consultation as Follow-Up Visit in Patients with Parkinsonism and Essential Tremor in during the Covid-19 Pandemic
  36. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease
  37. Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana
  38. Frontal functional connectivity and disease duration interactively predict cognitive decline in Parkinson's disease
  39. Incidencia y distribución geográfica de la enfermedad de Parkinson en México
  40. Malnutrition and Associated Motor and Non-motor Factors in People with Parkinson's Disease
  41. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease
  42. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  43. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  44. Teaching neurology to “Millennials:” Basic concepts and recommendations
  45. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  46. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  47. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  48. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  49. Análisis de subtipos motores en la enfermedad de Parkinson: Registro Mexicano de Enfermedad de Parkinson (ReMePARK)
  50. Air Pollution, Multiple Sclerosis and its Relevance to Mexico City
  51. Terapias de infusión en la enfermedad de Parkinson avanzada
  52. Brief historical review of Parkinson’s disease at 200 years of its description
  53. Diseño y evaluación curricular de un curso de posgrado de alta especialidad en medicina
  54. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  55. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  56. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  57. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  58. Etiología, fenomenología, clasificación y tratamiento de la distonía
  59. Indirect Costs of Parkinson Disease Health Care in the National Institute of Neurology and Neurosurgery in the Mexico City
  60. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  61. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  62. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  63. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  64. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative a...
  65. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  66. Spotlight on olfactory dysfunction in Parkinson's disease
  67. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  68. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  69. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  70. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  71. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  72. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  73. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  74. Theory of the mind in subjects with Parkinson's disease: A case-control study
  75. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  76. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  77. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  78. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  79. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  80. Electroconvulsive therapy in Parkinson´s disease
  81. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  82. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  83. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  84. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  85. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  86. Impulse control and related disorders in Mexican Parkinson's disease patients
  87. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  88. Simultaneous Presentation of Ocular Flutter in Two Sisters
  89. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  90. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  91. ¿Enfermedad de Parkinson o síndrome de enfermedad de Parkinson?
  92. Vas Eq-5d Utility Index In Parkinson’s Disease
  93. Direct Medical Costs Related To Parkinson’s Disease
  94. A reappraisal of the ten steps test for identifying atypical parkinsonism
  95. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  96. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  97. Cervical Dystonia
  98. Apathy and associated factors in Mexican patients with Parkinson’s disease
  99. Blood Pressure After Recent Stroke: Baseline Findings From the Secondary Prevention of Small Subcortical Strokes Trial
  100. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  101. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  102. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  103. Overweight is more prevalent in patients with Parkinson's disease
  104. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  105. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  106. A prospective series of patients with hyperglycaemia-associated movement disorders
  107. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  108. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  109. Sympathetic Cooling in an Optically Trapped Mixture of Alkali and Spin-Singlet Atoms
  110. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  111. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  112. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  113. SEQUENTIAL STAR FORMATION IN A COMETARY GLOBULE (BRC37) OF IC1396
  114. Uso clínico de autoanticuerpos en neurología
  115. Quality of life in patients with Parkinson's disease